The FDA's pace of approvals has held up despite staff cuts, with 23 novel drugs cleared by June — the most since 2023.
July 6, 2026 01:27 PM EDT
PharmaFDA+
FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years
Zachary Brennan
There’s an answer emerging on the multibillion-dollar question of whether the Trump administration’s gutting of FDA staff in April 2025 would slow down drug approvals: …
As leadership changes create more instability at the FDA, here’s what one former agency official thinks it will take to keep…
‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.
The FDA is looking to get thrifty with its approved drugs. | The framework would leverage existing safety data on approved drugs…
Makary pointed to three bottlenecks: hospital contracting, ethical reviews and approvals and the Investigational New Drug…
The country’s drug evaluation agency registered a jump in new drug and clinical trial applications, signaling a robust pivot…
The White House is reviewing a new FDA-biopharma user fee deal that includes
